Grifols (GRFS) stock gains as banks aim to finalize an €11B debt package for Brookfield's (BAM) plan to take the healthcare ...

Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 ...

Brookfield Asset Management is awaiting information from Grifols SA about related-party transactions as it seeks to complete ...

Mason Capital opposes Grifols sale to Brookfield Asset Management, raising concerns about the potential acquisition in the ...

Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% higher ...

Deutsche Bank raised the firm’s price target on Grifols (GRFS) to EUR 10 from EUR 9 and keeps a Hold rating on the shares. Published first on TheFly – the ultimate source for real-time, market-moving ...

Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of ...

EQS-News: Biotest AG / Key word (s): 9 Month figures Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million 14.11.2024 / 10:14 CET/CEST The issuer is solely responsible for ...

Berenberg Bank upgraded shares of Grifols (NASDAQ:GRFS – Free Report) to a strong-buy rating in a report released on Tuesday, Zacks.com reports. Grifols Price Performance Shares of NASDAQ GRFS opened ...

Overview: Grifols, S.A. is a plasma therapeutic company operating in Spain, the United States, Canada, and internationally with a market cap of approximately €6.40 billion. Operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...